India, Nov. 17 -- Pfizer on Monday announced the launch of a new migraine treatment in India. The company has introduced Rimegepant ODT, targeted at adults who have shown inadequate response to triptans, the commonly prescribed migraine drugs.
According to Pfizer Ltd, the medication offers rapid and long-lasting pain relief of up to 48 hours after treatment and is not linked to the risk of medication-overuse headaches.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....